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S U M M A R Y
Background: The adverse effects of yellow fever (YF) vaccine in dialysis patients are not well known.
There is concern about the risks and beneﬁts of the vaccine in immunocompromised patients living in
endemic areas, particularly given the risk of resurgence of urban YF with the spread of Aedes aegypti
mosquitoes. The purpose of this study was to assess the coverage and safety of YF vaccine in chronic
dialysis patients.
Methods: A cross-sectional study of 130 chronic dialysis patients was performed. Data were collected on
clinical characteristics and YF vaccine status. Patients not vaccinated against YF or without a booster
vaccination within the last 10 years were referred to receive the vaccine, and adverse effects were
monitored.
Results: Previous vaccination was veriﬁed in 44 patients within the last 10 years and in 26 patients at
more than 10 years ago, with no mention of adverse effects. Thirty-six patients had never been
vaccinated and 24 had an unknown vaccination status. Of the total 86 patients referred for
immunization, 45 actually received the YF vaccine, with 24.4% experiencing mild local adverse effects
and 4.4% experiencing fever. No serious adverse effects attributable to YF vaccine were observed
(anaphylaxis, neurological or viscerotropic disease).
Conclusions: YF vaccine coverage among hemodialysis patients is low, and the vaccine appeared to be
safe in this population with a small sample size.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite the past elimination of yellow fever (YF), its re-
emergence in the urban setting remains a threat in Brazil, since the
urban mosquito vector Aedes aegypti is widespread and this
sylvatic disease is expanding into the more densely populated
areas.1,2 YF control could be achieved either through vaccination or
vector control.1 The YF vaccine currently used in Brazil is the Bio-
Manguinhos 17DD viral attenuated vaccine produced at the
Oswaldo Cruz Institute.3
YF vaccine-associated side effects and serious adverse events
have been reported, including viscerotropic disease, neurological
disease, and severe hypersensitivity reactions.3 The US Vaccine
Adverse Event Reporting System (VAERS) observed a rate of
4.7 serious YF vaccine adverse events per 100 000 doses distributed.4* Corresponding author. Tel.: +55-16-3351-8340; fax: +55-16-3351-8382.
E-mail addresses: sigridsantos@gmail.com.br, sigridsantos@ufscar.br
(S. De Sousa dos Santos).
http://dx.doi.org/10.1016/j.ijid.2016.05.017
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The reporting rate was highest among persons aged 60 years
(8.3 per 100 000 doses). According to the Brazilian Ministry of Health
database, 1994 vaccine adverse events were notiﬁed between the
years 2000 and 2008, when 101 564 083 YF vaccine doses were
administered. The Bio-Manguinhos 17DD vaccine serious adverse
event rate was 0.9/100 000 doses for hypersensitivity reactions,
0.084/100 000 doses for neurological disease, and 0.026/
100 000 doses for viscerotropic disease, with no evidence of an
increased adverse event risk in older people.3
YF vaccine neurological and viscerotropic diseases do not seem
to be associated with the presence of any immunodeﬁciency or
organ failure. Apparently, certain speciﬁc immune disorders and
genetic factors may predispose the individual to viscerotropic
disease, such as systemic lupus erythematosus and thyroid
diseases.3,5 In a recent study in Brazil using passive surveillance
data, the age group 5–9 years was the most vulnerable to vaccine
neurotropic disease.6
Live attenuated vaccines are generally contraindicated in
pregnant women, immunocompromised patients, and children
under 6 months old.7 The recommendation for YF vaccine inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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immunosuppression and the epidemiological risk of YF.8 However,
reports of inadvertent vaccination of immunosuppressed patients
have not found signiﬁcant adverse effects or viscerotropic
disease.9,10
The geographic expansion of YF, with a continuous increase in
the area where vaccine is recommended in Brazil, justiﬁes the need
to study the potential adverse effects of vaccine in special
populations vulnerable to YF disease and candidates for the
vaccine.
Chronic kidney disease is characterized by immune dysfunction
and an increased risk of infection. Apparently the hypercytokine-
mia and the uremic milieu promote several immune disorders,
including neutrophil, monocyte, and lymphocyte dysfunction,
possibly predisposing the individual to YF vaccine adverse
effects.11,12
Sa˜o Carlos is a Brazilian municipality located in the central
region of the state of Sa˜o Paulo where YF vaccination is
recommended; this is considered a transition area for YF risk
because of a recent period of virus circulation.1,13,14
No speciﬁc recommendation for YF vaccine exists for renal
dialysis patients and patients with chronic renal disease.15,16 The
aim of this study was to assess the YF vaccination status and
vaccine safety in dialysis patients.
2. Methods
A cross-sectional study assessing the YF immunization of adult
patients with chronic kidney disease on regular dialysis therapy at
the Sa˜o Carlos Dialysis Service (Servic¸o de Nefrologia de Sa˜o
Carlos), Sa˜o Carlos, SP, Brazil, was performed from August 2012 to
March 2014. The Investigational Review Board of the Universidade
Federal de Sa˜o Carlos approved this study
(CAAE00631012.0.0000.5504). The Sa˜o Carlos Dialysis Service is
a hospital-based unit that has 29 dialysis stations, with two
isolation stations for patients with hepatitis B and hepatitis C,
respectively. All adult patients (over 18 years old) on regular
dialysis who agreed to participate and provided informed consent
were included in the study.
Patients underwent a structured interview and a review of
medical and immunization charts during dialysis sessions, using
an Epi Info version 3.5.1 questionnaire. Data were collected on sex,
age, provenance, comorbidities, alcohol intake, smoking, type of
kidney disease,17,18 duration of renal dysfunction and time on
dialysis, current dialysis method, previous kidney transplantation,
nutritional status,19 use of immunosuppressive therapy, and YF
vaccine status. Only immunization charts that had been ﬁlled out
with information on YF vaccine were considered. Verbal informa-
tion not recorded on the vaccination chart was ignored.
Patients not vaccinated against YF or without a booster
vaccination within the last 10 years were referred to receive the
vaccine at the nearest basic health unit. YF vaccine was considered
contraindicated in those with a severe immunodeﬁciency, deﬁned
by the diagnosis of a severe primary or secondary immunodeﬁ-
ciency, or by the use of high-dose steroids (at least 20 mg per day of
prednisone or equivalent doses of other steroids), cancer
chemotherapy, or radiation therapy in the last 3 months.7
The dialysis service operates three shifts per day, 6 days a week.
The patients were interviewed by three researchers. For the initial
evaluation, each researcher returned at least twice per shift to
interview all of the patients. After referring the patients for
vaccination, the researchers returned at least 10 times per shift
during the study period to assess compliance with the immuniza-
tion and any untoward medical occurrences within 30 days after
vaccination. Each patient was followed for at least 2 months. In the
case of difﬁculty in follow-up, patients were contacted bytelephone. Any adverse events were evaluated, counted, and
classiﬁed in terms of extension (local versus systemic) and nature
(fever, hypersensitivity, neurological, or viscerotropic disease).
Data were collected and analyzed using Epi Info version
3.5.1 software; a descriptive statistical analysis was performed.
Demographic, clinical, and YF vaccination characteristics of
chronic kidney disease patients on dialysis were described.
Frequency distribution tables were used for categorical variables
and dispersion measurements were used for quantitative vari-
ables. Subsequently, frequency and type of adverse events were
described in YF vaccinated patients.
3. Results
From a total of 181 chronic kidney disease patients on regular
dialysis treatment at the dialysis service, 130 were effectively
included in this study (Figure 1). Among the 35 patients who did
not sign the informed consent form, three were in a severe clinical
condition that required hospitalization and the other 32 did not
consent and refused to participate.
Most patients were male (63.8%) and white (50.8%); their mean
age was 53.9 years. Current smoking and alcohol intake were
reported by 13.8% and 12.3% of the patients, respectively. The most
common comorbidities were hypertension (83.8%) and diabetes
mellitus (26.9%). Vascular disease was the leading cause of renal
loss (41.5%), followed by diabetes mellitus (23.1%), tubulointer-
stitial disease (16.2%), and glomerular disease (12.3%). The median
time on dialysis was 12 months (interquartile range 4–48 months).
Thirteen patients had returned to dialysis after kidney graft failure,
and one of them was on low-dose corticosteroid therapy. The
majority of patients (70%) had a normal weight; six were in a state
of emaciation (4.6%) and the remaining patients were overweight/
obese to some degree (23.1%) (Table 1).
Previous YF vaccination within the last 10 years was observed
in 44 patients (33.8%), and more than 10 years ago in 26 patients
(20%), with no mention of adverse effects. Thirty-six patients had
never been vaccinated (27.7%) and 24 patients had an unknown
vaccination status (18.5%).
Of the total 86 patients with an indication for YF revaccination,
only 45 actually received the vaccine after referral. Patients were
undergoing hemodialysis three times a week in sessions lasting
3–5 h each. Some of them had transport barriers, such as low
income and limited mobility. Some patients complained that it was
necessary to go to the basic health unit more than once to obtain
the YF vaccine. At the end of the study, the remaining
41 unvaccinated patients were referred again to receive the YF
vaccine.
Among the 45 effectively vaccinated patients, 21 had never
been vaccinated before, nine had an unknown vaccination status,
and 15 had been vaccinated more than 10 years ago (Figure 1).
Adverse events were reported by 12/45 vaccinated patients
(26.7%); mild local adverse events occurred in 11/45 patients,
with pain in all of them and edema in three patients. Six patients
who complained of local pain and three patients who reported
localized edema had received a pneumococcal vaccine on the same
day. Two patients developed fever, which resolved less than 24 h
later. No patient developed anaphylaxis, or viscerotropic or
neurological disease (Table 2).
4. Discussion
The present study found a low YF vaccine coverage in dialysis
patients, with an occasional occurrence of minor adverse reactions.
Sa˜o Carlos is considered a transitional area for the risk of YF
transmission, and YF vaccination with a booster every 10 years is
recommended in this area.7 There is concern whether this
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Figure 1. Flow diagram of patients with chronic kidney disease on dialysis included in the study (YF, yellow fever; *referred for YF vaccination).
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services.
Despite the recommendation, the proportion of hemodialysis
patients who had been vaccinated less than 10 years ago was low
(33%). The patients who were up to date with the YF vaccine hadTable 1
Demographic, clinical, and pathological characteristics of 130 dialysis patients at
the Servic¸o de Nefrologia de Sa˜o Carlos—2013
Characteristic Total YF vaccinated
patientsa
Sex, male, n (%) 83 (63.8) 32 (71.1)
Age, years, mean  SD 53.9  14.9 53.8  15.2
Color/ethnicity, n (%)
White 66 (50.8) 26 (57.8)
Brown 44 (33.8) 16 (35.6)
Black 18 (13.8) 2 (4.4)
Yellow 1 (0.8) 0 (0.0)
Indigenous 1 (0.8) 1 (2.2)
Smoking, n (%) 18 (13.8) 7 (15.6)
Alcohol intake, n (%) 16 (12.3) 5 (11.1)
Comorbidities, n (%)
Systemic arterial
hypertension
109 (83.8) 36 (80)
Diabetes mellitus 35 (26.9) 14 (31.1)
Cancer 6 (4.6) 1 (2.2)
Skin 2 (1.5) 1 (2.2)
Prostate 2 (1.5) 0 (0.0)
Mouth and kidney 1 (0.8) 0 (0.0)
Multiple myeloma 1 (0.8) 0 (0.0)
Rheumatologic diseases 2 (1.5) 0 (0.0)
Pathological type of kidney
disease, n (%)
Vascular disease 54 (41.5) 19 (42.2)
Diabetes mellitus 30 (23.1) 11 (24.4)
Tubulointerstitial disease 21 (16.2) 7 (15.6)
Glomerular disease 16 (12.3) 3 (6.7)
Polycystic kidney disease 4 (3.1) 2 (4.4)
Unknown 3 (2.3) 2 (4.4)
Graft loss 2 (1.5) 1 (2.2)
Duration of renal failure,
months, median (IQR)
25 (8–84) 36 (8–96)
Time on dialysis, months,
median (IQR)
12 (4–48) 24 (5–48)
Kidney transplant, n (%) 13 (10) 5 (11.1)
Use of immunosuppressive drugs 1 (0.8) 0 (0.0)
YF, yellow fever; SD, standard deviation; IQR, interquartile range.
a Patients who were referred and received YF vaccine during the study period.been vaccinated during the 2008 immunization campaign, when
cases of the disease occurred in the region .20
More recently, the guidelines of the Brazilian national immuni-
zation policy have recommended a single booster dose at 10 years
after the primary YF vaccination .21 However, even considering the
new World Health Organization (WHO) recommendation of a single
dose of YF vaccine to confer lifelong protection,22 there would be
only 70 patients (53.8%) with adequate YF vaccination. The
26 patients vaccinated more than 10 years ago had received
the YF vaccine in the year 1992. This was probably associated with
the introduction of YF vaccine in the routine immunization services
of permanently endemic areas in 1991.23 There was no report of
adverse events in the 70 subjects who had previously been
vaccinated, but the data may be underestimated.
Of the 86 dialysis patients with chronic renal failure who were
referred for vaccination against YF, only 45 actually received the
vaccine. This was probably due to several factors, such as non-
availability of the YF vaccine in dialysis centers and vaccine
hesitance among patients and health care workers.24,25 The
irregularity in vaccine availability in basic health units certainly
played an important role in reducing vaccine uptake.26
YF vaccine is contraindicated for people with a severe
immunodeﬁciency, malignant neoplasm, transplantation, or
whose immunological response is affected by drugs or radiation,
because they are presumably at increased risk of serious adverse
events.22 Patients with thymus disorders, such as thymoma or
myasthenia gravis, are demonstrably more vulnerable to YF
vaccine-associated serious adverse events.27 However, there is
growing evidence that YF vaccine is relatively safe in mild or
moderately immunocompromised patients, such as in asymptom-
atic HIV-infected patients,28 rheumatologic patients on immuno-
suppressants,10 and even in some organ transplanted patients.9
In line with population-based studies and pharmacovigilance
databases,29 and although chronic renal failure is associated with
both cellular and humoral immune dysfunction, no serious YF
vaccine adverse effects occurred during the follow-up of these
patients (anaphylaxis, neurological or viscerotropic disease). The
high frequency of mild local adverse effects was probably
associated with the concomitant use of anti-pneumococcal
vaccine.
Despite YF vaccine appearing to be safe in patients with chronic
renal dialysis, the data obtained in this study are not robust enough
Table 2
Adverse effects of yellow fever vaccination in 45 dialysis patients at the Servic¸o de Nefrologia de Sa˜o Carlos—2013
Patient Sex Age, years Comorbidity Kidney disease Transplant Duration of
renal failure,
months
Time on dialysis,
months
YF vaccine adverse
effects
Locala Systemic
1b F 64 AH VD No 72 12 P No
2 F 55 AH/DM DM No 48 48 P No
3b M 51 None UN No 132 60 P/E No
4 M 46 None UN No 7 4 P Fever
5 M 60 AH/DM DM No 8 6 P No
6 F 31 AH GL Yes 122 96 No Fever
7 M 59 AH PKD Yes 156 156 P No
8b F 32 AH/DM DM No 12 1 P/E/R No
9b M 42 AH TD No 60 6 P No
10b F 73 AH/DM DM No 24 24 P/E/R No
11b F 52 AH/DM DM No 48 12 P/R No
12 F 57 AH VD No 9 6 P No
F, female; M, male; AH, arterial hypertension; DM, diabetes mellitus; VD, vascular disease; UN, unknown; GL, graft loss; PKD, polycystic kidney disease; TD, tubulointerstitial
disease.
a P, pain; E, edema; R, redness.
b Concomitant pneumococcal vaccination.
T. Facincani et al. / International Journal of Infectious Diseases 48 (2016) 91–9594to strongly recommend YF vaccine for all dialysis patients. Further
studies with aggregate data should be performed. Conclusions
regarding the safety of YF vaccine in dialysis patients are limited by
the small study population and by the fact that prior YF vaccination
could have diminished the expected incidence of serious adverse
effects, so far only reported in ﬁrst-time vaccinees.
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